Clin2
NCT05238792Possibly a fitRecruiting

Immune cells to treat high-risk solid tumors in children

Solid Tumor

Part of Cancer clinical trials.

This trial tests a type of immunotherapy using special white blood cells (T-cells) that are trained to find and attack cancer cells. It is for children and young adults with high-risk solid tumors that have not gone away or have come back after standard treatment.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
24 people
Ages
1 year to 70 years
Study type
Interventional

Who can take part

  • Your child must have one of these cancers: Ewing sarcoma, Wilms tumor, neuroblastoma, rhabdomyosarcoma, soft tissue sarcoma, or osteosarcoma.
  • The cancer must be high risk, meaning it has not responded to standard treatment, has come back, or is still present after treatment.
  • A blood test must show that your child's tissue type (HLA) matches the study's requirements.
  • Your child must be between 1 and 69 years old.
  • Your child must not have taken systemic steroids within the last week before starting the study treatment.
  • Your child must be well enough to perform daily activities at 50% or more (Karnofsky/Lansky score).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT03891706Recruiting· Phase 1
Personalized T-cell therapy for advanced solid tumors

This early-phase study tests personalized immune cells (T cells) made from your own tumor and blood to treat advanced solid cancers. It may help your immune system recognize and attack your tumor, especially if standard treatments no longer work.

Guangzhou, Gaungdong
NCT05831033Recruiting· Early Phase 1
Your own immune T-cells to treat advanced solid tumors

This early-phase study tests a treatment made from your own tumor-fighting immune cells (TIL cells) for advanced solid cancers that have worsened or no longer respond to standard therapy. The main goal is to learn whether it is safe and whether it can shrink tumors for people who have limited options.

Shanghai, Shanghai Municipality
NCT06524024Not yet recruiting
Personalized immune cell therapy for solid tumors

This trial tests a personalized cell therapy (tumor polypeptide DC-CTL) for adults with solid tumors such as colorectal, lung, or breast cancer. The goal is to see if infusing your own immune cells trained to attack cancer can help control the disease.

NCT07172958Recruiting· Phase 1
Immune cell therapy for children with certain solid tumors

This trial tests a new type of immune cell therapy called CAR T cells that are designed to recognize and attack cancer cells in children and young adults with certain solid tumors that have come back or not responded to standard treatment.

Washington D.C., District of Columbia
NCT06193759Recruiting· Phase 1
Immune cell therapy for malignant pediatric brain tumors

This trial tests a new immune therapy using your child's own specially trained white blood cells to fight brain tumors. The treatment is given directly into the fluid around the brain, and it is for children with specific types of brain cancer.

Washington D.C., District of Columbia
NCT02203903Recruiting· Phase 1
Donor T-cell treatment after transplant for high-risk AML and MDS

This Phase 1 trial studies an advanced form of donated immune cells given after a stem cell transplant to help prevent leukemia coming back. It mainly looks at safety and whether the treatment can work in people with very high-risk AML or MDS who have not relapsed.

Washington D.C., District of Columbia

Hear when a new Solid Tumor trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.